  Apelin is a neuro-vasoactive peptide that plays a major role in the control
of cardiovascular functions and water balance, but has an in-vivo half-life in
the minute range, limiting its therapeutic use. We previously developed
LIT01-196, a systemically active metabolically stable apelin-17 analog,
produced by chemical addition of a fluorocarbon chain to the N-terminal part of
apelin-17. LIT01-196 behaves as a potent full agonist for the apelin receptor
and has an in vivo half-life in the bloodstream of 28 min after intravenous
(i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious
normotensive rats. We aimed to investigate the effects of LIT01-196 following
systemic administrations on arterial blood pressure, heart rate, fluid balance
and electrolytes in conscious normotensive and hypertensive deoxycorticosterone
acetate (DOCA)-salt rats. Acute i.v. LIT01-196 administration, in increasing
doses, dose-dependently decreases arterial blood pressure with ED 50 values of
9.8 and 3.1 nmol/kg in normotensive and hypertensive rats, respectively. This
effect occurs for both via a nitric oxide-dependent mechanism. Moreover, acute
s.c. LIT01-196 administration (90 nmol/kg) normalizes arterial blood pressure
in conscious hypertensive DOCA-salt rats for more than 7 h. The
LIT01-196-induced blood pressure decrease remains unchanged after 4 consecutive
daily s.c. administrations of 90 nmol/kg, and does not induce any alteration of
plasma sodium and potassium levels and kidney function as shown by the lack of
change in plasma creatinine and urea nitrogen levels. Activating the apelin
receptor with LIT01-196 may constitute a novel approach for the treatment of
hypertension.
